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Abstract Purpose: To determine
the incidence of and risk factors for
adverse cardiac events during cate-
cholamine vasopressor therapy in
surgical intensive care unit patients
with cardiovascular failure. Meth-
ods: The occurrence of any of seven
predefined adverse cardiac events
(prolonged elevated heart rate,
tachyarrhythmia, myocardial cell
damage, acute cardiac arrest or death,
pulmonary hypertension-induced
right heart dysfunction, reduction of
systemic blood flow) was prospec-
tively recorded during catecholamine
vasopressor therapy lasting at least
12 h. Results: Fifty-four of 112
study patients developed a total of
114 adverse cardiac events, an inci-
dence of 48.2 % (95 % CI,
38.8–57.6 %). New-onset tachyar-
rhythmia (49.1 %), prolonged
elevated heart rate (23.7 %), and
myocardial cell damage (17.5 %)
occurred most frequently. Aside from
chronic liver diseases, factors inde-
pendently associated with the
occurrence of adverse cardiac events
included need for renal replacement
therapy, disease severity (assessed by
the Simplified Acute Physiology
Score II), number of catecholamine
vasopressors (OR, 1.73; 95 % CI,
1.08–2.77; p = 0.02) and duration of
catecholamine vasopressor therapy
(OR, 1.01; 95 % CI, 1–1.01;
p = 0.002). Patients developing
adverse cardiac events were on cate-
cholamine vasopressors (p \ 0.001)
and mechanical ventilation
(p \ 0.001) for longer and had longer
intensive care unit stays (p \ 0.001)
and greater mortality (25.9 vs. 1.7 %;
p \ 0.001) than patients who did not.
Conclusions: Adverse cardiac
events occurred in 48.2 % of surgical
intensive care unit patients with car-
diovascular failure and were related
to morbidity and mortality. The
extent and duration of catecholamine
vasopressor therapy were indepen-
dently associated with and may
contribute to the pathogenesis of
adverse cardiac events.
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Introduction
Cardiovascular failure is one of the leading causes of death
in surgical intensive care unit (SICU) patients [1]. Aside
from fluids, the vast majority of pharmacological agents
used to treat cardiovascular failure are catecholamine
derivatives or drugs interacting with adrenergic post-
receptor pathways [2]. Despite their widespread use [3],
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catecholamine vasopressor drugs carry a high potential to
induce adverse side effects and increase the risk of in-
hospital mortality [4]. As a result of the ubiquitous distri-
bution of adrenergic receptors, catecholamine-associated
side effects can impair several organ functions, but are most
serious when affecting heart function [5].
Adverse cardiac events may include prolonged ele-
vated heart rate, tachyarrhythmia, myocardial ischemia
and cell damage, cardiac arrest, pulmonary artery hyper-
tension-induced right heart dysfunction, and reduction of
systemic blood flow [5]. Adverse cardiac events can
perpetuate cardiovascular failure and worsen patient
outcome. Although the potential of catecholamine vaso-
pressors to induce adverse side effects in general, and
adverse cardiac events in particular, is well known, their
actual incidence has not been systematically reported thus
far. Determination of the true burden of adverse cardiac
events during catecholamine vasopressor therapy could
help clinicians to better assess the risk of unwanted
adrenergic effects affecting the heart and stimulate
research to identify alternative non-adrenergic treatment
strategies for cardiovascular failure.
In this prospective observational study, the incidence
of seven predefined adverse cardiac events was system-
atically evaluated in 112 consecutive SICU patients with
cardiovascular failure during catecholamine vasopressor
therapy. Furthermore, we sought to determine indepen-
dent risk factors for the occurrence of adverse cardiac
events and appraise the association between catechol-
amine vasopressor exposure as well as different
catecholamine vasopressor drugs and the occurrence of
adverse cardiac events. Our hypothesis was that adverse
cardiac events frequently occur during catecholamine
vasopressor therapy and that catecholamine vasopressor
support is associated with both morbidity and mortality.
Patients and methods
This prospective observational study was performed
between January 1 and December 31, 2009, in a 12-bed
general and surgical ICU in a tertiary university teaching
hospital. The study protocol was reviewed by the Ethics
Committee of Innsbruck Medical University. Since no
blood was sampled, patient treatment was not affected by
study enrollment, and as exclusively anonymous data
were retrieved, written informed consent was waived.
Inclusion and exclusion criteria
All SICU patients with cardiovascular failure—defined as
a mean arterial pressure less than 65 mmHg despite
adequate fluid resuscitation and blood flow requiring
catecholamine vasopressor therapy for at least 12 h—
were eligible for study enrollment. Catecholamine vaso-
pressor therapy was defined as infusion of one or more of
the following drugs: norepinephrine, epinephrine, phen-
ylephrine, and/or dopamine at dosages greater than 5 lg/
kg/min. Age less than 18 years, pregnancy, non-surgical
critical illness, and limitation/withholding of intensive
care therapy were exclusion criteria.
Hemodynamic and general patient management
The institutional hemodynamic management has been
described before [6]. SICU patients with cardiovascular
failure were routinely monitored with an arterial and central
venous line. A pulmonary artery or transpulmonary ther-
modilution catheter (PiCCO plus; Pulsion, Munich,
Germany) was placed at the discretion of the attending
physician. Transesophageal echocardiography was used
liberally in patients without cardiac output measurement.
Fluid resuscitation was performed according to the response
of arterial blood pressure, filling pressures (e.g., central
venous pressure, pulmonary arterial occlusion pressure),
stroke volume variation, and/or stroke volume/cardiac index
to repetitive fluid loading using crystalloids or gelatine-
based colloids (Gelofusin; B. Braun, Melsungen, Ger-
many). If cardiac index remained less than 2–2.5 L/min/m2
or central/mixed venous oxygen saturation was less than
60 % despite volume loading and/or blood transfusion,
milrinone (0.3–0.7 lg/kg/min) and/or epinephrine was
continuously infused. Norepinephrine (Arterenol; Sanofi-
Aventis, Frankfurt, Germany) was infused to increase mean
arterial blood pressure to greater than 60–65 mmHg. In
septic shock, hydrocortisone (200–300 mg/day) was added
as a continuous infusion if escalating norepinephrine doses
could not stabilize hemodynamic function. On the basis of
clinical symptoms, erythrocyte concentrates were transfused
to maintain hemoglobin above 70 g/L. Endotracheally
intubated patients were sedated, whenever required, by
infusing sufentanil and midazolam or morphine alone.
Continuous veno-venous hemofiltration (CVVH) was
employed for renal indications only.
Data documentation
Upon study enrollment, the following data were collected
in all patients: age, gender, body mass index, premorbid
conditions, type of surgery, cause of cardiovascular fail-
ure, the Simplified Acute Physiology Score II (SAPS II)
[7], the Sequential Organ Failure Assessment (SOFA)
score [8], heart rate, mean arterial blood pressure, cen-
tral venous pressure, serum troponin T concentrations
(Modular E, Roche Diagnostics GmbH, Mannheim,
Germany; detection limit 5–10,000 ng/L), the type, dose,
and number of catecholamine vasopressor drugs infused,
the overall catecholamine vasopressor load, as well as
the need for mechanical ventilation, intra-aortic balloon
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pump and/or renal replacement therapy. Because different
catecholamine vasopressor drugs were used, the over-
all catecholamine vasopressor load was calculated
according to the formula suggested by Russell et al. [9]:
vasopressor load (lg/kg/min) = norepinephrine (lg/kg/
min) ? [dopamine (lg/kg/min/kg)]/2 ? epinephrine (lg/
kg/min) ? [phenylephrine (lg/kg/min)]/10. Upon SICU
discharge, the duration of catecholamine vasopressor
therapy and mechanical ventilation, length of SICU stay,
and mortality were documented.
Adverse cardiac events
Using a standardized protocol, we recorded the occurrence
of any of the following adverse cardiac events during
catecholamine vasopressor therapy: prolonged elevated
heart rate, tachyarrhythmia, myocardial cell damage, acute
cardiac arrest, acute cardiac death, pulmonary artery
hypertension-induced right heart dysfunction, and reduc-
tion of systemic blood flow (Table 1). Each time an
adverse cardiac event occurred, the type and dose of the
catecholamine vasopressor infused as well as the overall
catecholamine vasopressor load was recorded.
Statistical analysis
Assuming a 50 % incidence of adverse cardiac events
during catecholamine vasopressor therapy [10, 11], a
sample size calculation revealed that inclusion of 110
patients could predict the incidence of adverse cardiac
events with a 95 % confidence interval (CI) extending by
9.3 % in both directions.
All statistical analyses were performed with the SPSS
software package (SPSS 13.0.1; SPSS Inc., Chicago,
Illinois, USA). Descriptive methods were applied to
determine the incidence of adverse cardiac events. Com-
parisons between patients with or without adverse cardiac
events as well as between specific subgroups (patients with
or without cardiac surgery, patients with or without chronic
cardiovascular diseases) were performed using the Mann–
Whitney U test, Fisher’s exact test, and the chi-squared
test, as applicable. To determine independent risk factors
for the occurrence of adverse cardiac events, a multivariate
logistic regression model was calculated. Variables
showing significant (p \ 0.1) or clinically relevant differ-
ences between patients with or without adverse cardiac
events in a bivariate analysis (for statistical tests applied
see above) were included in the multivariate regression
model. If variables exhibited collinearity between each
other (correlation coefficient greater than 0.4) the one with
the highest correlation coefficient was included in the
multivariate regression model. Since we sought to specif-
ically evaluate the association between catecholamine
vasopressor exposure and the occurrence of adverse car-
diac events, regression models were built for each aspect of
catecholamine vasopressor exposure (vasopressor load at
study enrollment, number of catecholamine vasopressors
infused at study enrollment, duration of catecholamine
vasopressor therapy) and each catecholamine vasopressor
drug (binary use and dose at study enrollment). p values
less than 0.05 were considered to indicate statistical sig-
nificance. All data are presented as median values with
interquartile ranges (IQRs), unless otherwise indicated.
Results
During the observation period, 422 patients were admitted
to the SICU. One hundred and twelve patients (26.5 %)
Table 1 Definition of adverse cardiac events during catecholamine vasopressor infusion
Prolonged elevated heart rate Sinus or non-sinus (in patients with chronic non-sinus rhythm) tachycardia[95 bpm for[12
consecutive hours
Myocardial cell damage New increase of troponin T above detection threshold or increase by [25 % of baseline
serum troponin T concentrations. In cardiac surgery patients, serum troponin T
concentrations had to remain elevated ([25 % of baseline concentrations) [48 h after
surgery
Tachyarrhythmia New non-sinus tachycardia or tachyarrhythmia [95 bpm for [5 min
Acute cardiac arrest Unexpected cardiac arrest (asystole, ventricular fibrillation, or pulseless electrical activity
with absent pulse) with return of spontaneous circulation following cardiopulmonary
resuscitation
Acute cardiac death Unexpected cardiac arrest (asystole, ventricular fibrillation or pulseless electrical activity
with absent pulse) without return of spontaneous circulation despite cardiopulmonary
resuscitation
Pulmonary artery hypertension-induced
right heart dysfunction
Applicable for patients monitored with a pulmonary artery catheter: new increase of mean
pulmonary arterial pressure [25 mmHg associated with an increase of central venous
above pulmonary artery occlusion pressure and a stroke volume index \30 mL/m2 or
requirement for inotropic agents
Reduction of systemic blood flow Applicable for patients monitored with either a pulmonary artery or transpulmonary
thermodilution catheter: persistent ([6 h) reduction of cardiac output by [20 % from
baseline, need for or [20 % increase in inotropic support ([6 h)
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were eligible for enrollment and were included. One
hundred and fourteen new-onset adverse cardiac events
occurred in 54 patients during catecholamine vasopressor
therapy (Table 2), an incidence of 48.2 % (95 % CI,
38.8–57.6 %). No difference in the rate and type of
adverse cardiac events was observed between patients
with or without cardiac surgery as well as between
patients with or without chronic cardiovascular diseases
(Table 2). In 17 patients, an adverse cardiac event already
existed at study enrollment. These patients could only be
screened for the development of other adverse cardiac
events.
Patients developing one or more adverse cardiac
events more frequently suffered from chronic liver dis-
eases and had a higher SAPS II than patients without
adverse cardiac events (Table 3). At study enrollment,
patients who subsequently developed adverse cardiac
events presented with higher heart rates and serum tro-
ponin T concentrations, were treated with epinephrine
more frequently and with phenylephrine at a higher dos-
age, received more catecholamine vasopressors
simultaneously, had higher vasopressor loads and SOFA
scores, and required continuous veno-venous hemofiltra-
tion more often than patients who did not develop adverse
cardiac events (Table 4). Until SICU discharge, patients
experiencing adverse cardiac events required catechol-
amine vasopressor therapy and mechanical ventilation for
a longer time, stayed in the SICU longer, and had higher
mortality than those without adverse cardiac events
(Table 4).
The vasopressor load at the time adverse cardiac events
occurred differed between single adverse cardiac events
(Fig. 1). Chronic liver disease, need for renal replace-
ment therapy, the SAPS II, the number of catecholamine
vasopressor drugs infused at study enrollment, and the
duration of catecholamine vasopressor therapy were inde-
pendently associated with the occurrence of adverse
Table 2 Incidence of adverse cardiac events during catecholamine vasopressor therapy
Total Cardiovascular surgery Chronic cardiovascular diseases
Yes No p value Yes No p value
n 112 43 69 94 18
Patients with one or more adverse cardiac events 54 (48.2) 25 (58.1) 29 (42) 0.12 44 (46.8) 10 (55.6) 0.61
Total number of adverse events 114 61 53 90 24
Median number (IQR) of adverse cardiac events 1 (1–3) 2 (1–3) 1 (1–2) 0.26 1.5 (1–3) 1 (1–2.3) 0.26
Patients experiencing one adverse cardiac event 30 (50.6) 12 (48) 18 (62.1) 0.41 22 (50) 8 (80) 0.16
Patients experiencing two adverse cardiac events 10 (18.5) 5 (20) 5 (17.2) 1 10 (22.7) 0 0.18
Patients experiencing three or more
adverse cardiac events
14 (25.9) 8 (32) 6 (20.7) 0.37 12 (27.3) 2 (20) 1
Type of adverse cardiac event
New-onset tachyarrhythmia 56 (49.1) 34 (55.7) 22 (23.7) 0.14 42 (30) 14 (43.8) 0.36
Prolonged elevated heart rate 27 (23.7) 13 (21.3) 14 (15.1) 0.66 21 (15) 6 (18.8) 1
Myocardial cell damage 20 (17.5) 7 (8.9) 13 (14) 0.09 18 (12.9) 2 (6.3) 0.24
Reduction of systemic blood flow 6 (5.3) 3 (3.8) 3 (3.2) 1 5 (3.6) 1 (3.1) 1
Acute cardiac arrest 4 (3.5) 4 (5.1) 0 0.06 4 (2.9) 0 0.58
Pulmonary artery hypertension-induced
right heart dysfunction
1 (0.9) 0 1 (1.1) 0.46 0 1 (3.1) 0.21
Data are presented as absolute numbers with percentage in parentheses, unless otherwise indicated. No study patient experienced acute
cardiac death
Table 3 Demographic and clinical data of study patients
No adverse
cardiac event
Adverse
cardiac event
p value
n 58 54
Age (years) 69 (61–75) 68 (60–75) 0.71
Male gender n (%) 42 (72.4) 30 (55.6) 0.08
Body mass index 26 (24–29) 25 (23–28) 0.36
Premorbid conditions n (%)
Arterial hypertension 44 (75.9) 36 (66.7) 0.3
Coronary artery disease 27 (46.6) 20 (37) 0.34
Congestive heart failure 23 (39.7) 28 (51.9) 0.26
Chronic renal insufficiency 19 (32.8) 22 (40.7) 0.44
Asthma/COPD 14 (24.1) 17 (31.5) 0.41
Diabetes mellitus 12 (20.7) 10 (18.5) 0.82
Chronic liver disease 1 (1.7) 9 (16.7) 0.007*
Type of surgery n (%)
Abdominal 21 (36.2) 18 (33.3) 0.84
Cardiovascular 18 (31) 25 (46.3) 0.12
Orthopedic 10 (17.2) 4 (7.4) 0.16
Thoracic 6 (10.3) 6 (11.1) 1
Other 3 (5.2) 1 (1.9) 0.62
Cause of cardiovascular failure n (%)
Sepsis 23 (39.7) 21 (38.9) 1
SIRS 19 (32.8) 15 (27.8) 0.68
Post-cardiac surgery/
cardiogenic
9 (15.5) 12 (22.3) 0.47
Others 7 (12.1) 6 (11.1) 1
Admission SAPS II (points) 38 (32–47) 49 (37–55) 0.002*
Data are presented as median values with IQRs, unless otherwise
indicated
COPD chronic obstructive pulmonary disease, SIRS systemic
inflammatory response syndrome
* Significant difference between groups
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cardiac events (Table 5; Fig. 2). When binary use and the
dose of single vasopressive agents at study enrollment were
introduced into the multivariate model, use of epinephrine
(OR 3.35; CI 95 % 1.27–8.87; p = 0.02) and the dose of
phenylephrine (OR 2.1; CI 95 % 1.04–4.26; p = 0.04)
were independently associated with the occurrence of
adverse cardiac events.
Discussion
In this prospective observational study, a 48.2 % inci-
dence of adverse cardiac events was detected in 112 SICU
patients with cardiovascular failure during catecholamine
vasopressor therapy. Patients who developed adverse
cardiac events had higher catecholamine vasopressor
loads, were on catecholamine vasopressor drugs for
longer, and had greater morbidity and mortality than
patients who did not. In addition to chronic liver disease,
need for renal replacement therapy, and disease severity
(assessed by the SAPS II), the number of catecholamine
vasopressor agents infused and the duration of catechol-
amine vasopressor therapy were independently associated
with adverse cardiac events. Of the four vasopressor
agents applied, epinephrine and phenylephrine were
associated with the occurrence of adverse cardiac events.
The finding that nearly half of our study population
developed adverse cardiac events during catecholamine
vasopressor therapy should stimulate reflection. In view
Table 4 Clinical data at study
enrollment and SICU discharge No adverse
cardiac event
Adverse
cardiac event
p value
n 58 54
Study enrollment
Heart rate (bpm) 85 (75–96) 95 (84–110) 0.003*
Mean arterial pressure (mmHg) 75 (65–85) 70 (65–80) 0.17
Central venous pressure (mmHg) 11 (9–14) 12 (11–15) 0.22
Epinephrine n (%) 11 (19) 23 (42.6) 0.008*
Epinephrine dose (lg/kg/min) 0.08 (0.04–0.12) 0.1 (0.05–0.13) 0.43
Norepinephrine n (%) 25 (43.1) 29 (53.7) 0.34
Norepinephrine dose (lg/kg/min) 0.26 (0.13–0.4) 0.31 (0.12–0.54) 0.31
Dopamine n (%) 25 (43.1) 16 (29.6) 0.17
Dopamine dose (lg/kg/min) 3.3 (2.5–5.4) 4.2 (3.1–6.5) 0.23
Phenylephrine n (%) 28 (48.3) 22 (40.7) 0.45
Phenylephrine dose (lg/kg/min) 1.42 (0.74–2.01) 2.43 (1.66–2.91) 0.007*
Number of catecholamine vasopressors n 1 (1–2) 2 (1–3) 0.02*
Catecholamine vasopressor load (lg/kg/min) 0.18 (0.07–0.35) 0.28 (0.17–0.5) 0.003*
Supplementary AVP therapy n (%) 1 (1.7) 0 1
Troponin T serum concentrations (lg/L) 0.1 (0.01–0.8) 0.9 (0.03–2.6) 0.007*
Pulmonary artery catheter n (%) 24 (41.4) 29 (53.7) 0.26
Tp thermodilution catheter n (%) 1 (1.7) 3 (5.6) 0.35
Need for mechanical ventilation n (%) 49 (84.5) 49 (90.7) 0.4
Need for CVVHF n (%) 1 (1.7) 8 (14.8) 0.01*
SOFA score (points) 10 (8–12) 11 (9–13) 0.04*
SICU discharge
Time on vasopressor support (h) 57 (39–111) 186 (84–312) \0.001*
Time on mechanical ventilation (days) 4 (1–10) 9 (5–18) \0.001*
Length of SICU stay (days) 6 (3–12) 15 (8–28) \0.001*
SICU mortality n (%) 1 (1.7) 14 (25.9) \0.001*
Data are presented as median values with IQRs, unless otherwise indicated
AVP arginine vasopressin, Tp transpulmonary
* Significant difference between groups
Fig. 1 Median values and IQRs of vasopressor loads at occurrence
of single adverse cardiac events. *Significant difference in the
vasopressor load at occurrence of single adverse cardiac events;
PEHR prolonged elevated heart rate (n = 56), aMI acute myocar-
dial ischemia and cell damage (n = 27), TA tachyarrhythmia
(n = 20), RedSBF reduction in systemic blood flow (n = 6). The
vasopressor load at occurrence of acute cardiac arrest [n = 4; 0.1
(0.03–0.22) lg/kg/min] and pulmonary artery hypertension-
induced right heart dysfunction (n = 1; 0.34 lg/kg/min) were not
included because of their low incidence
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of the current lack of alternative drugs to treat cardio-
vascular failure, catecholamine vasopressor agents should
be used judiciously, and catecholamine-sparing strategies
should be pursued. Such strategies may include the
enforcement of adequate fluid and inotropic resuscitation,
targeting reasonable cardiovascular endpoints (e.g., tissue
perfusion instead of arbitrary arterial blood pressure
targets), and the avoidance of practices which again might
increase the need for catecholamine vasopressors (e.g.,
non-targeted sedation). In addition, future research is
required to identify alternative vasopressive drugs for the
treatment of cardiovascular failure.
Considering that this study specifically evaluated
adverse cardiac events, the true incidence of adverse
systemic events during catecholamine vasopressor ther-
apy is likely to be even higher, as suggested by other
studies [9, 12–14]. Since this was an observational study,
no conclusions on the cause of adverse cardiac events can
be drawn. Cardiovascular failure [15, 16], disease severity
[17–19], acute kidney injury [20], and chronic liver dis-
eases [21] have been associated with cardiac pathologies
and, as suggested by the multivariate regression model,
played a role in the pathogenesis of adverse cardiac
events in this population as well. Pharmacologic effects of
catecholamine vasopressors on the heart would support a
causative association with the occurrence of adverse
cardiac events [22–27]. Such drug-related effects may
influence the heart directly through stimulation of alpha
and beta receptors [27] or indirectly through alpha-
receptor-mediated vasoconstriction and increased ven-
tricular afterload [28, 29]. These negative effects might be
reduced by a catecholamine-sparing treatment regimen
through adding vasopressin to the treatment plan which
has been shown to significantly reduce norepinephrine
requirement without increasing the risk of serious adverse
events in vasodilatory shock states [30].
Although indicated by a weak trend in the adjusted
regression model, an independent association between the
catecholamine vasopressor dose at study enrollment and
the development of adverse cardiac events was not
observed. There may be several reasons for the absence of
Table 5 Associations between clinical variables and the occurrence
of adverse cardiac events
Unit OR 95 % CI p value
Model I (r2 = 0.3)
Vasopressor load lg/kg/min 1.47 0.93–2.31 0.1
SAPS II points 1.04 1.01–1.08 0.02*
Need for CVVHF 7.33 0.82–65.8 0.08
Chronic liver disease 17.16 1.89–156 0.01*
Model II (r2 = 0.33)
Number of vasopressors n 1.73 1.08–2.77 0.02*
SAPS II points 1.05 1.02–1.09 0.004*
Need for CVVHF 10.9 1.15–104.14 0.04*
Chronic liver disease 15.5 1.67–143.61 0.02*
Model III (r2 = 0.44)
Duration of vasopressor
therapy
h 1.01 1–1.01 0.002*
SAPS II points 1.05 1.01–1.09 0.02*
Need for CVVHF 4.06 0.35–47.66 0.27
Chronic liver disease 12 1.34–107.51 0.03*
Because of collinearity with catecholamine vasopressor exposure
and a lower correlation coefficient with the occurrence of adverse
cardiac events, heart rate, serum troponin T concentrations and the
Sequential Organ Failure Assessment score at study enrollment
were not entered in the multivariate models
OR odds ratio
* Independent association with occurrence of adverse cardiac
events
Fig. 2 Incidence of adverse cardiac events as predicted by
catecholamine vasopressor exposure (adjusted logistic regression
models). *Independent association with the occurrence of adverse
cardiac events. Each logistic regression model was adjusted for the
SAPS II, need for continuous veno-venous hemofiltration, and
presence of chronic liver disease. Quartiles of catecholamine
vasopressor load: 1, B0.12 lg/kg/min; 2, 0.13–0.25 lg/kg/min; 3,
0.26–0.45 lg/kg/min; 4, C0.46 lg/kg/min; quartiles of duration of
vasopressor therapy: 1, B61 h; 2, 66–151 h; 3, 158–346 h; 4,
C348 h
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a dose–response effect in our study. First, the catechol-
amine vasopressor doses included in the regression
models were not recorded at the time the adverse cardiac
event occurred. Second, single adverse cardiac events
occurred at different vasopressor doses, indicating that a
wide range of critical catecholamine doses can induce
single adverse cardiac events. Furthermore, moderate r2
values (0.3–0.44) suggest that other factors not included
in the regression models played a role in the pathogenesis
of adverse cardiac events during catecholamine vaso-
pressor therapy. Interestingly, these factors do not appear
to include specific surgical subpopulations (e.g., cardio-
vascular surgery) or common chronic conditions such as
arterial hypertension, coronary artery disease, or conges-
tive heart failure, but may comprise individual factors
such as genetic predisposition [31].
In view of the small number of patients receiving
single vasopressive agents, data on the association
between particular catecholamine agents and the occur-
rence of adverse cardiac events must be interpreted with
caution. In our analysis, epinephrine and phenylephrine
were the catecholamine agents independently associated
with the occurrence of adverse cardiac events. While the
binary use but not the dose of epinephrine was associated
with the occurrence of adverse cardiac events, phenyl-
ephrine was linked with the occurrence of adverse cardiac
events in a dose-dependent fashion. Although no causa-
tive association has so far been proven in the clinical
setting, adverse cardiac events have been reported with
both catecholamine agents [32–34].
The two adverse cardiac events most frequently
observed in this study were tachyarrhythmia and pro-
longed elevated heart rate, both of which were correlated
with significant morbidity and mortality. A close rela-
tionship between the use of catecholamine vasopressor
drugs and the occurrence of tachycardia and/or tachyar-
rhythmia has been reported by several authors [35, 36].
Particularly striking was the 17.9 % incidence of myo-
cardial cell damage, as reflected by increases in troponin
T serum levels during catecholamine vasopressor therapy.
Given that troponin T serum levels can be influenced by
renal function, we chose to consider only relevant (greater
than 25 %) increases in serum troponin T levels to reflect
myocardial cell damage. In cardiac surgery patients, this
was done 48 h after surgery, a time interval during which
troponin usually decreases [37]. Indeed, troponin T levels
increased by a median percentage of 52 % (95 % CI,
28–99 %) in patients with detectable troponin T at study
enrollment (n = 8).
Given that a reduction in systemic blood flow and
pulmonary artery hypertension-induced right heart dys-
function could only be detected in patients monitored with
a pulmonary artery or transpulmonary thermodilution
catheter, it must be assumed that the true incidence of these
adverse cardiac events was underestimated in our popu-
lation. Compared to other adverse cardiac events, however,
the incidence of pulmonary artery hypertension-induced
right heart dysfunction appears low, suggesting that this
may not be a common complication during catecholamine
vasopressor therapy. Myocardial stunning, diastolic dys-
function, and increased afterload may all explain persistent
reductions in systemic blood flow during vasopressor
infusion [25]. Although most studies evaluating the effect
of catecholamine vasopressors, such as norepinephrine, on
hemodynamics reported unchanged or increased cardiac
output [38], our data indicate that at least some patients
may experience a relevant reduction in systemic blood
flow which may, in conjunction with peripheral vasocon-
striction, precipitate tissue hypoperfusion.
Additional limitations need to be considered when
interpreting our study results. By enrolling 112 patients,
we could report the incidence of adverse cardiac events
during catecholamine vasopressor therapy with a 95 % CI
of 39–58 %. Inclusion of a larger patient population
would have allowed more accurate determination of the
incidence of adverse cardiac events. Taking into account
that an incidence in the lower ranges of the 95 % CI
would still be clinically relevant, inclusion of more
patients would have most likely not changed the clinical
conclusion of this study. The list of adverse cardiac events
systematically screened for in this study is incomplete and
lacks pathologies which are difficult to assess at the
bedside (e.g., myocardial cell apoptosis [39]). Further-
more, our results cannot be extrapolated to other
non-SICU populations. Surgery triggers a systemic
inflammatory response which may itself predispose to the
development of adverse cardiac events during catechol-
amine vasopressor therapy. Despite considering multiple
constellations of various vasopressive agents, different
adverse cardiac events, and finally different confounding
factors, we failed to identify a critical cumulative dose of
a particular vasopressive agent or a particular combina-
tion of vasopressive agents which was associated with
adverse cardiac events. Finally, the reported incidence of
adverse cardiac events during catecholamine vasopressor
therapy must be closely interpreted together with the
institutional hemodynamic protocol applied. It is con-
ceivable that the incidence of adverse cardiac events
varies if different resuscitation strategies are applied.
In conclusion, adverse cardiac events occur in almost
half of SICU patients during catecholamine vasopressor
therapy and are related to both morbidity and mortality.
Although our study cannot prove a causative relationship,
the extent and duration of catecholamine vasopressor
therapy were independently associated with and may
contribute to the pathogenesis of adverse cardiac events.
Clinicians need to be aware of this high incidence of
adverse cardiac events when starting SICU patients on
catecholamine vasopressor drugs.
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